Check the activity agenda
Friday, March 22, 2024
Room 1
10:50-12:00
PLENARY SESSION 1
Opening Session
Use of methylation in Meningiomas
Treatment update on recurrent and aggressive meningioma
Targeting BRAF in pediatric brain tumors
Moderator: Andrés Cervio (Argentina)
Moderator: Clarissa Baldotto (RJ)
Moderator: ícaro Thiago de Carvalho (SP)
Opening Session
Use of methylation in Meningiomas
Speaker: Martha Quezado (Estados Unidos)
Treatment update on recurrent and aggressive meningioma
Speaker: Andreas Hottinger (Suíça)
Targeting BRAF in pediatric brain tumors
Speaker: Jason Fangusaro (Estados Unidos)
Monday, March 23, 2024
Room 1
13:30-15:30
SESSION 4: DIFFUSE GLIOMAS
A Critical Overview of Targeted Therapies for Glioma
Translational research for gliomas: future landscapes and emerging paradigm
The role of CAR T cell therapy in neurooncology
What we do know about non-standard of care treatments for gliomas: cannabis, antidepressants, metformin and others
Bevacizumab, is there still a role for antiangiogenics in glioblastoma?
The optimal timing of palliative care in glioma patients
How feasible is surgery in the motor area?
Discussion
Moderator: ícaro Thiago de Carvalho (SP)
A Critical Overview of Targeted Therapies for Glioma
Speaker: Tracy Batchelor (Estados Unidos)
Translational research for gliomas: future landscapes and emerging paradigm
Speaker: Vinay K. Puduvalli (Estados Unidos)
The role of CAR T cell therapy in neurooncology
Speaker: Andreas Hottinger (Suíça)
What we do know about non-standard of care treatments for gliomas: cannabis, antidepressants, metformin and others
Speaker: Yvonne Kew (Estados Unidos)
Bevacizumab, is there still a role for antiangiogenics in glioblastoma?
Speaker: Juan Sepulveda (Espanha)
The optimal timing of palliative care in glioma patients
Speaker: Daniel Neves Forte (SP)
How feasible is surgery in the motor area?
Speaker: Lorenzo Bello (Itália)
Discussion